Neuropharm shares plummet as lead candidate fails autism Phase III trial
This article was originally published in Scrip
Neuropharm's lead candidate, NPL-2008, a formulation of the SSRI antidepressant fluoxetine, has failed to meet the primary endpoint of reducing repetitive behaviour in autism in the Phase III SOFIA study, sending its shares down by 83% to close at £0.17 on February 18th on the London Stock Exchange.
You may also be interested in...
Somaxon Pharmaceuticals and Procter & Gamble Pharmaceuticals are to co-promote Somaxon's insomnia drug Silenor (low-dose doxepin) in the US.
GlaxoSmithKline has begun the Phase III clinical trials programme for its adjuvanted vaccine candidate (GSK1437173A) against herpes zoster for the prevention of shingles.
The EMA has accepted Optimer Pharmaceuticals' MAA for its narrow-spectrum antibiotic fidaxomicin for the treatment of Clostridium difficile infection (CDI) and for the prevention of recurrences of CDI.